Search research articles
Contact Us
Filters
Showing results (1-10 of 296) with videos related to
Page
of 30
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2025
Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non-Small Cell Lung Cancer
Martin Schuler
The Lancet. Oncology
|
October 30, 2020
The quest for efficient trial designs in precision oncology
Martin Schuler
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen
|
May 14, 2013
[Medical care of the cancer patient - Is it really so different?]
Martin Schuler
Future Oncology (London, England)
|
April 24, 2014
LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer
Jens Köhler, Martin Schuler
Onkologie
|
September 21, 2013
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review
Jens Köhler, Martin Schuler
Leukemia & Lymphoma
|
April 18, 2009
Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention
Claudia Stolz, Martin Schuler
European Journal of Cancer (Oxford, England : 1990)
|
February 6, 2014
Targeted therapies in gastroesophageal cancer
Stefan Kasper, Martin Schuler
Current Drug Targets
|
November 1, 2006
Therapeutic targeting of apoptotic pathways in cancer
Johannes Meiler, Martin Schuler
European Journal of Cancer (Oxford, England : 1990)
|
January 9, 2021
Shall we use steroids when treating patients with lung cancer with checkpoint inhibitors?
Niels Reinmuth, Martin Schuler
Expert Review of Anticancer Therapy
|
August 3, 2011
Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies
Daniel C Christoph, Martin Schuler
Page
of 30
Search research articles
Search
Showing results (1-10 of 296) with videos related to
Sort By:
Page
of 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2025
Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non-Small Cell Lung Cancer
Martin Schuler
The Lancet. Oncology
|
October 30, 2020
The quest for efficient trial designs in precision oncology
Martin Schuler
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen
|
May 14, 2013
[Medical care of the cancer patient - Is it really so different?]
Martin Schuler
Future Oncology (London, England)
|
April 24, 2014
LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer
Jens Köhler, Martin Schuler
Onkologie
|
September 21, 2013
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review
Jens Köhler, Martin Schuler
Leukemia & Lymphoma
|
April 18, 2009
Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention
Claudia Stolz, Martin Schuler
European Journal of Cancer (Oxford, England : 1990)
|
February 6, 2014
Targeted therapies in gastroesophageal cancer
Stefan Kasper, Martin Schuler
Current Drug Targets
|
November 1, 2006
Therapeutic targeting of apoptotic pathways in cancer
Johannes Meiler, Martin Schuler
European Journal of Cancer (Oxford, England : 1990)
|
January 9, 2021
Shall we use steroids when treating patients with lung cancer with checkpoint inhibitors?
Niels Reinmuth, Martin Schuler
Expert Review of Anticancer Therapy
|
August 3, 2011
Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies
Daniel C Christoph, Martin Schuler
Page
of 30